Liertinib Tablets (trade name: Aoyixin) is an oral targeted anticancer drug indicated primarily for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring specific epidermal growth factor receptor (EGFR) gene mutations. It delivers precision therapy against EGFR mutations, covering two clinical settings: first-line treatment for patients with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations, and second-line treatment for those with confirmed EGFR T790M mutation. By inhibiting tumor growth signaling pathways, the drug features an innovative structural design that enhances both efficacy and safety profiles.
Indications for Use
Liertinib Tablets is specifically indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in the following scenarios:
First-line treatment
For patients who have not received prior EGFR-targeted therapy and are confirmed to harbor EGFR exon 19 deletion or exon 21 (L858R) substitution mutation.
Second-line treatment
For patients with disease progression following prior EGFR-targeted therapy and confirmed positive for EGFR T790M mutation.
Dosage and Administration
Administration shall be strictly in accordance with the physician’s instructions, with dosage adjustments based on treatment lines:
First-line treatment
80 mg (1 tablet) per dose, twice daily. May be taken with or without food.
Second-line treatment
160 mg (2 tablets) per dose, twice daily.
Specification
80 mg per tablet.
The tablets are pink film-coated, and appear white after the coating is removed.
Basic Drug Information
Active Ingredient: Liertinib
Drug Classification: Class 1 New Chemical Entity
Approval Number: National Medical Product Administration (NMPA) Approval H20250004
As an innovative drug, it adopts a unique naphthylamine structural design that differentiates it from other drugs in the same class. This design confers higher molecular stability, which contributes to enhanced antitumor activity and reduced adverse reactions.
Precautions
EGFR mutation status must be confirmed via genetic testing prior to administration to ensure suitability of treatment.
Common adverse reactions include rash and diarrhea. Regular monitoring of liver and kidney functions is recommended during treatment.
The drug is contraindicated in pregnant women, lactating women, and individuals hypersensitive to any component of the formulation.
For detailed medication guidance, consult a qualified healthcare provider.
